Hospers GAP - Search Results

1

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.

Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Lee KA, et al. Among authors: hospers gap. Nat Med. 2022 Mar;28(3):535-544. doi: 10.1038/s41591-022-01695-5. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228751 Free PMC article.

2

The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.

Hospers GA, de Vries EG, Mulder NH. Hospers GA, et al. Br J Cancer. 1990 Jan;61(1):79-82. doi: 10.1038/bjc.1990.18. Br J Cancer. 1990. PMID: 2153398 Free PMC article.

3

A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.

Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG. Hospers GA, et al. Int J Cancer. 1990 Jul 15;46(1):138-44. doi: 10.1002/ijc.2910460125. Int J Cancer. 1990. PMID: 2163989

4

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Meijer C, Mulder NH, Hospers GA, Uges DR, de Vries EG. Meijer C, et al. Br J Cancer. 1990 Jul;62(1):72-7. doi: 10.1038/bjc.1990.232. Br J Cancer. 1990. PMID: 2390486 Free PMC article.

5

Mechanisms of cellular resistance to cisplatin.

Hospers GA, Mulder NH, De Vries EG. Hospers GA, et al. Med Oncol Tumor Pharmacother. 1988;5(3):145-51. doi: 10.1007/BF02986437. Med Oncol Tumor Pharmacother. 1988. PMID: 3045443 Review.

6

Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer.

Mulder NH, Dolsma WV, Mulder PO, De Vries EG, Willemse PH, Sleijfer DT, Hospers GA, Van der Graaf WT. Mulder NH, et al. Anticancer Res. 1995 Jul-Aug;15(4):1565-8. Anticancer Res. 1995. PMID: 7654046 Clinical Trial.

7

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects.

Hospers GA, Eisenhauer EA, de Vries EG. Hospers GA, et al. Br J Cancer. 1999 May;80(5-6):629-38. doi: 10.1038/sj.bjc.6690404. Br J Cancer. 1999. PMID: 10360638 Free PMC article. Review.

8

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.

Schröder CP, de Vries EG, Mulder NH, Willemse PH, Sleijfer DT, Hospers GA, van der Graaf WT. Schröder CP, et al. J Antimicrob Chemother. 1999 May;43(5):741-3. doi: 10.1093/jac/43.5.741. J Antimicrob Chemother. 1999. PMID: 10382902 Clinical Trial.

9

Delirium after interleukin-2 and alpha-interferon therapy for renal cell carcinoma.

van Steijn JH, Nieboer P, Hospers GA, de Vries EG, Mulder NH. van Steijn JH, et al. Anticancer Res. 2001 Sep-Oct;21(5):3699-700. Anticancer Res. 2001. PMID: 11848546

10

Renal failure after treatment with interferon alpha 2b.

Roeloffzen WW, Hospers GA, De Vries EG, Navis GJ. Roeloffzen WW, et al. Anticancer Res. 2002 May-Jun;22(3):1929-31. Anticancer Res. 2002. PMID: 12168896

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page